



December 13, 2007
07-024
[non-proprietary version]

Mr. James Dyer
Director, Office of Nuclear Reactor Regulation
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555-0001

Subject: Notice of Intent to Submit an Application to License and Operate a Medical Isotope Production System

This letter serves as notification of the Babcock and Wilcox Company (B&W) intent to license and operate a Medical Isotopes Production System (MIPS) []
The MIPS License Application will include a small non-power low-enriched aqueous homogenous reactor system, and associated processing systems to produce Molybdenum-99 for use in the medical industry.

B&W plans to submit a combined construction and operating license application as early as July of 2009 with pre-licensing discussions to begin in 2008. This notice is provided to facilitate your resource and budget planning. As part of the pre-licensing discussions and process, B&W intends to propose solutions to and request NRC disposition of potential policy issues related to the licensing and operation of the facility that have been identified and are key to the success of the project. These key policy or regulatory issues will be provided to the NRC as early as possible in 2008 for decisions to support project planning.

The plans and schedule for the MIPS have not yet been publicly announced therefore, B&W is requesting this information and the accompanying affidavit be withheld from public disclosure. The affidavit sets forth the basis on which the information may be withheld under the conditions of 10CFR2.390.

Sincerely,

[signature on file with proprietary letter]

S. Robert Cochran,
President, B&W Technical Services Group